Current news and events

Tor Erik Rusten's research presented:Autophagy - Hope or Threat to Cancer Patients?

Tor Erik Rusten (photo: Berit Langaard, OUS)

Tor Erik Rusten is heading the Tumor-Host Biology research group at the Department of Molecular Cell Biology at the Institute for Cancer Research. His research on autophagy has recently (May 23rd) been presented in a feature article in popular science form, published on the Oslo University Hospital home page (in Norwegian), entitled "Autophagy - Hope or Threat to Cancer Patients?".

Clinical Trials Day - May 20th 2019Clinical studies - the road to better treatment

Jon B. Borgaard
The International Clinical Trials Day (ICTD) provides an opportunity to increase the awareness of clinical trials among the general public. We want to emphasize that clinical trials are essential for developing better treatments. We need more patients who take part in clinical trials, and we'd like to see that the number of clinical trials increase. The ICTD in many countries alsoprovides a well-deserved ‘time out’ to recognize the people who conduct clinical trials and to say “thanks” for what they do every day to improve public health. This day of celebration provides these communities with a unique opportunity to raise awareness of clinical trials – and of clinical research as a career option – among the greater public.
 
In connection with the "Clinical Trial Day" 2019 Jon B. Borgaard, head of the CTU department at Oslo University Hospital, has written a blog (in Norwegian) entitled "Clinical studies - the road to better treatment".

New genes linked to bipolar disorder

Ole Andreassen

A recent international large-scale study that included NORMENT has identified new genes in the human DNA that increase the risk of developing bipolar disorder.

The results were recently published in the prestigious journal Nature Genetics. Professor Ole A. Andreassen from the Division of Mental Health and Addiction at OUH and NORMENT was among the leaders of the study, and 13 NORMENT researchers and Norwegian collaborators also contributed.

Radforsk to invest NOK 4.5 million in cancer research

Anette Weyergang

Radforsk is an evergreen investor focusing on companies that develop cancer treatment. Since its start-up in 1986, Radforsk has ploughed NOK 200 million of its profit back into cancer research at Oslo University Hospital. This year, four researchers will be awarded a total of NOK 4.5 million. One of them is Anette Weyergang, who will receive NOK 3.75 million over a three-year period.

The first Norwegian CAR

Made in Oslo by a team of researchers from Oslo University Hospital, the first ever Norwegian CAR T cell is now a fact. A potential treatment based on this result depends on a clinical study.
The CAR (Chimeric Antigen Receptor) construct was designed, manufactured and validated in two laboratories in the Radium Hospital campus. One is headed by Else Marit Inderberg and Sébastien Wälchli and the other is led by June Helen Myklebust and Erlend B. Smeland.

At OUH Rikshospitalet 8-10 May 2019:The 13th International Symposium on Medical Information and Communication Technology

Oslo University Hospital is the host of the 13th International Symposium on Medical Information and Communication Technology (ISMICT 2019), which will be held at OUH Rikshospitalet on 8-10 May 2019. General chair is Ilangko Balasingham from The Intervention Centre.  
This year’s conference continues its tradition of being the premier forum for presentation of results on cutting-edge research in medical information and communication technology (ICT). 

Successful kick-off for new collaboration between Institute for Cancer Research and Institut Curie

Cancer researchers from Institute for Cancer Research, Oslo, and Institut Curie, Paris, held a successful kick-off seminar in Paris on March 25th, followed by a reception with Norway’s ambassador in France.

Thanks to a generous donation from Trond S. Paulsen, a new collaboration between ICR and Institut Curie, Paris, was opened. The funded project, “Mechanisms of cancer cell invasion” (InvaCell), is a collaboration between the groups of Harald Stenmark, ICR, and Philippe Chavrier, Institut Curie.

Protonics team leader presenting their research on The Scientist's Channel

Dr. Theodossis Theodossiou discusses his team’s cutting-edge research into curing cancer with photodynamic therapy (PDT). PDT is an exciting anti-cancer treatment, currently used clinically. It works by using light, a photo-activatable drug and oxygen to kill cancer. With the specificity of the treatment relying on the application of light.

In this video, Dr. Theodossiou describes how his team are working to improve the efficiency and accuracy of PDT through a variety of methods.

A revolutionary technique for faster and more accurate regional anesthesia

Axel R. Sauter (left) and Leiv Arne Rosseland

Philips, B.Braun and Oslo University Hospital, represented by Axel R. Sauter and Leiv Arne Rosseland from the Division of Emergencies and Critical Care, have partnered in the EU funded INTUI-VIEW project to develop, validate, and bring to the market an intelligent needle tracking technology using ultrasound imaging.

The collaboration has successfully resulted in a market launch of a completely new solution, with the potential to revolutionise the field of regional anesthesia.


More news from the archive